AFT Pharmaceuticals Share Purchase Plan Oversubscribed

103372.5 - 1148048-2






Not for release to US wire services or distribution to the US

Market and Media release 1 July 2020
AFT Pharmaceuticals Share Purchase Plan Oversubscribed
AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce that its
NZ$2 million share purchase plan (SPP) has closed oversubscribed. The SPP received
strong shareholder support with AFT receiving applications totalling approximately
NZ$9.8 million. Applications will be scaled on a proportionate basis in accordance
with the number of AFT shares held by applicants on the SPP record date (9 June
2020). Refunds of surplus application amounts paid will be made to applicants in
accordance with the terms of the SPP offer document.
The SPP was offered to all eligible existing AFT shareholders with a registered address
in New Zealand or Australia, enabling them to each subscribe for up to a maximum
of NZ$50,000 / A$47,000 of new AFT shares. 1,554 AFT shareholders applied under the
SPP with an average application of approximately NZ$6,306.00
The SPP is part of AFT’s capital raising announced on 10 June 2020, whereby AFT also
undertook a fully underwritten NZ$10 million placement of new shares to select
investors in both local and offshore markets and certain major shareholders sold
down NZ$63.8 million of existing shares (together, the Placement). The new shares
under the SPP will be issued at the same price as the Placement share price, being
NZ$3.75 per share.
AFT Managing Director Hartley Atkinson said: “We are delighted with the response to
both the SPP and the earlier placement. The success of these initiatives represents a
recognition of the global opportunities AFT enjoys and the progress we have made
over an extended period. They also represent an endorsement of our strategy to

103372.5 - 1148048-2
Pg. 2
realise our potential. We thank investors and we are working hard to reward their
support.”
Allotment of all shares issued under the SPP is expected to occur on 2 July 2020.
Trading of those shares is expected to commence on NZX on 2 July 2020 and on ASX
on 3 Ju ly 2020. The new shares to be issued under the SPP will rank equally in all
respects with AFT’s existing ordinary shares on allotment.
ENDS
- Released for and on behalf of AFT Pharmaceuticals Limited by Chief Financial Officer Malcolm Tubby
For more information
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals +64 21 645 643
Tel: +64 9 488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad
portfolio of pharmaceutical products across a wide range of therapeutic categories which are
distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription
and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes
patented, branded and generic drugs. Our business model is to develop and in-license products for sale
by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain
Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of
the world.
Not for release or distribution in the United States
This announcement has been prepared for publication in New Zealand and Australia and may not be
released to US wire services or distributed in the United States. This announcement does not constitute an
offer of securities for sale in the United States or any other jurisdiction. Any securities described in this
announcement may not be offered or sold in the United States absent registration under the US Securities
Act of 1933 or an exemption from registration.